Physician profile
Danielle Blake
NPI 1144836701
$34,379.17
in general payments reported to CMS, 2019-2025
18 companies · $7,863 in 2025
The $7,863 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $1,135 · 2023: $4,991 · 2024: $20K · 2025: $7,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $5,407 · Food and Beverage: $4,295 · Consulting Fee: $350 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,880.00 |
| Travel and Lodging | $5,406.62 |
| Food and Beverage | $4,295.33 |
| Consulting Fee | $350.00 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $30,083.58 | 2022-2025 | Ojjaara |
| Janssen Biotech, INC. | $918.18 | 2021-2025 | Tecvayli, Talvey, Darzalex |
| Beigene USA, INC. | $785.59 | 2022-2025 | Brukinsa |
| Pfizer INC. | $468.82 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $348.84 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $314.91 | 2023-2025 | Amvuttra |
| Adaptive Biotechnologies Corporation | $291.46 | 2023 | Clonoseq |
| Amgen INC. | $270.85 | 2023-2024 | Blincyto, Nplate |
| Syndax Pharmaceuticals, INC. | $152.91 | 2025 | Revuforj |
| Jazz Pharmaceuticals INC. | $143.85 | 2025 | |
| Genentech USA, INC. | $138.66 | 2023 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $129.60 | 2024 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $122.55 | 2022 | |
| Astellas Pharma US INC | $95.00 | 2022 | |
| Beone Medicines USA, INC. | $39.28 | 2025 | Brukinsa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $31.76 | 2025 | Yescarta |
| Janssen Scientific Affairs, LLC | $28.08 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.